Premium
Stenting and Angioplasty for Idiopathic Intracranial Hypertension: A Case Series with Clinical, Angiographic, Ophthalmological, Complication, and Pressure Reporting
Author(s) -
Teleb Mohamed S.,
Cziep Matthew E.,
Issa Mohammad,
Lazzaro Marc,
Asif Kaiz,
Hun Hong Sang,
Lynch John R.,
Fitzsimmons BrianFred M.,
Remler Bernd F.,
Zaidat Osama O.
Publication year - 2013
Publication title -
journal of neuroimaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.822
H-Index - 64
eISSN - 1552-6569
pISSN - 1051-2284
DOI - 10.1111/jon.12072
Subject(s) - medicine , angioplasty , stenosis , surgery , headaches , papilledema , complication , radiology , sinus (botany) , medical record , radiological weapon , botany , biology , genus
BACKGROUND Previous studies have demonstrated that cerebral dural sinus stenosis (DSS) may be a potential patho‐physiological cause of idiopathic intracranial hypertension (IIH). Endovascular therapy for DSS is emerging as a potential alternative to treat IIH. Here, we present the results of our case series. METHOD We prospectively collected angiographic and manometric data on patients that underwent angioplasty/stenting for IIH. All patients had failed maximal medical therapy (MMT) and had confirmed sinus stenosis. Demographic, clinical and radiological presentation, and outcomes were collected retrospectively. RESULTS A total of 18 patients underwent 25 procedures. Demographics revealed a mean age of 30 (range 15‐59), 83% (15/18) were female, 72% (13/18) were white, and mean body mass index of 36 (range 23‐59.2). All patients presented with classic IIH. Symptom improvement or resolution was reported in 94% (17/18) of patients. All patients had resolution and/or stabilization/improvement of their papilledema. Headaches related to increased pressure improved in 56% (10/18). Re‐stenosis and retreatment occurred in 33% (6/18). No procedural related complications were reported. CONCLUSION Dural sinus angioplasty and stenting is relatively safe, feasible, and clinically efficacious for patients with symptomatic sinus stenosis who have failed standard therapy. The long‐term durability of patency and clinical improvement remains unknown.